Literature DB >> 22126729

Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain.

C Grávalos1, P García-Alfonso, R Afonso, V Arrazubi, A Arrivi, J C Cámara, J Capdevila, A Gómez-España, A Lacasta, J L Manzano, M Salgado, J Sastre, E Díaz-Rubio.   

Abstract

In Spain 22,000 new cases of colorectal cancer are diagnosed each year, with 13,075 deaths resulting from this disease. Around 70% of colorectal cancers are localised in the colon and 30% in the rectum. A group of Spanish experts established recommendations on what would be the best strategy in the treatment of locally advanced rectal cancer (LARC). Adequate assessment of local tumour extension, including high-resolution magnetic resonance imaging and endorectal ultrasound, is essential for successful treatment. The three cornerstones in the treatment of LARC are surgery, radiotherapy and chemotherapy. Most patients will need a total mesorectal excision (TME). Preoperative chemo-radiotherapy (CRT) is preferred for the majority of patients with T3/T4 disease and/or regional node involvement, and adjuvant chemotherapy is recommended after a patient-sharing decision. Capecitabine, after showing a trend in improved downstaging in neoadjuvant stratum and the convenience of its oral administration, represents an alternative to 5-FU as perioperative treatment of LARC.

Entities:  

Mesh:

Year:  2011        PMID: 22126729     DOI: 10.1007/s12094-011-0747-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  62 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

3.  Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.

Authors:  M M Borner; P Schoffski; R de Wit; F Caponigro; G Comella; A Sulkes; G Greim; G J Peters; K van der Born; J Wanders; R F de Boer; C Martin; P Fumoleau
Journal:  Eur J Cancer       Date:  2002-02       Impact factor: 9.162

4.  Patient preferences for oral versus intravenous palliative chemotherapy.

Authors:  G Liu; E Franssen; M I Fitch; E Warner
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

5.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

6.  Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.

Authors:  Nam Kyu Kim; Seung Hyuk Baik; Jin Sil Seong; Hoguen Kim; Jae Kyung Roh; Kang Young Lee; Seung Kook Sohn; Chang Hwan Cho
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

7.  A modern regimen of pre-operative concurrent chemo-radiation therapy in locally advanced rectal cancer.

Authors:  Shouki Bazarbashi; Mazen El-Bassiouni; Mahmoud Abdelsalam; Hussein Soudy; Nasser Al Sanea; Alaa Abdul Jabbar; Mohamed Manji; Mosa Fagih; Dahish Ajarim
Journal:  J Surg Oncol       Date:  2008-09-01       Impact factor: 3.454

8.  A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer.

Authors:  Robert de W Marsh; Thomas J George; Tariq Siddiqui; William M Mendenhall; Robert A Zlotecki; Stephen Grobmyer; Steven Hochwald; Myron Chang; Bradley Larson; Judy King
Journal:  Am J Clin Oncol       Date:  2010-06       Impact factor: 2.339

9.  Laparoscopic-assisted versus open abdominoperineal resection for low rectal cancer: a prospective randomized trial.

Authors:  Simon S M Ng; Ka Lau Leung; Janet F Y Lee; Raymond Y C Yiu; Jimmy C M Li; Anthony Y B Teoh; Wing Wa Leung
Journal:  Ann Surg Oncol       Date:  2008-04-05       Impact factor: 5.344

10.  Long-term results of intersphincteric resection for low rectal cancer.

Authors:  Reza Chamlou; Yann Parc; Tabassome Simon; Malika Bennis; Nidal Dehni; Rolland Parc; Emmanuel Tiret
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.